Long-Term Safety of NGX-4010, a High-Concentration Capsaicin Patch, in Patients with Peripheral Neuropathic Pain

David M. Simpson, Suzanne Gazda, Stephen Brown, Lynn R. Webster, Shiao Ping Lu, Jeffrey K. Tobias, Geertrui F. Vanhove

Research output: Contribution to journalArticlepeer-review

92 Scopus citations


Context: Postherpetic neuralgia (PHN) and painful human immunodeficiency virus-associated distal sensory polyneuropathy (HIV-DSP) are peripheral neuropathic pain syndromes that are difficult to treat. Current treatment options are often limited by poor tolerability. Objectives: The objective of the current open-label study was to assess the safety of repeated applications of NGX-4010, a high-concentration capsaicin patch (capsaicin 8%), over one year, in patients with moderate to severe PHN or HIV-DSP. Methods: Patients had successfully completed a previous NGX-4010 study and had a pain level appropriate for further treatment. Eligible patients had not been treated with NGX-4010 within 12 weeks of study initiation. Patients received pretreatment with a topical local anesthetic (lidocaine 4%) for 60 minutes followed by either a 60-minute (PHN and HIV-DSP patients) or a 90-minute (HIV-DSP patients) treatment with NGX-4010. Patients could receive up to three additional treatments at intervals of ≥12 weeks. Regardless of the number of treatments received, all patients were followed up for 48 weeks except for those withdrawing early. Results: A total of 106 patients were enrolled and received a total of 293 NGX-4010 treatments. The most frequently reported treatment-emergent adverse events were transient, mild-to-moderate application site erythema, pain, edema, and papules. Small, transient pain-related increases in blood pressure during and immediately after NGX-4010 application were observed. There was no evidence of an increased incidence of adverse events, dermal irritation, intolerability, or impaired neurological function with repeated treatments. Conclusion: It is concluded that repeated treatments with NGX-4010 administered over a one-year period are generally safe and well tolerated.

Original languageEnglish
Pages (from-to)1053-1064
Number of pages12
JournalJournal of Pain and Symptom Management
Issue number6
StatePublished - Jun 2010


  • HIV-associated distal sensory polyneuropathy
  • Peripheral neuropathic pain
  • capsaicin
  • postherpetic neuralgia


Dive into the research topics of 'Long-Term Safety of NGX-4010, a High-Concentration Capsaicin Patch, in Patients with Peripheral Neuropathic Pain'. Together they form a unique fingerprint.

Cite this